MIV-210

Therapy Area
An NRTI for treatment experienced HIV and/or hepatitis B (HBV) patients.

  
Competitive Edge
Against both multiresistant HIV and HBV that has become multiresistant to other drugs on the market.
Licensee
Hainan Noken is developing MIV-210 as a potential treatment against hepatitis B.

Last Modified: 05/09/2008